GSKGlaxoSmithKlineRunning, no new patients
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 208 (final count)
- Started
- Oct 7, 2019
- Main results expected
- Apr 17, 2025
- Fully finished
- Mar 11, 2027
- Results posted
- May 6, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Randomized Across Sub-studies
Measured over: Day 1
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04126200 · record last updated 2026-05-06 · checked 2026-11-09 15:47 UTC